Article
Medicine, General & Internal
Mukul Bhattarai, Mohsin Salih, Manjari Regmi, Mohammad Al-Akchar, Radhika Deshpande, Zurain Niaz, Abhishek Kulkarni, Momin Siddique, Shruti Hegde
Summary: This meta-analysis supports the effectiveness of SGLT2 inhibitors in improving cardiovascular morbidity and mortality in selected patients. However, SGLT2 inhibitors were not associated with a reduced risk of acute myocardial infarction. Future long-term prospective studies are needed to further understand the long-term cardiovascular benefits.
Review
Cardiac & Cardiovascular Systems
Yao Hao Teo, Yao Neng Teo, Nicholas L. Syn, Cheryl Shumin Kow, Celine Shuen Yin Yoong, Benjamin Y. Q. Tan, Tiong-Cheng Yeo, Chi-Hang Lee, Weiqin Lin, Ching-Hui Sia
Summary: SGLT2 inhibitors have shown positive effects on cardiovascular outcomes in patients without diabetes mellitus, particularly in reducing cardiovascular deaths and heart failure hospitalizations in heart failure patients. Additionally, these inhibitors have beneficial metabolic effects, such as weight and blood pressure control, in patients without diabetes mellitus.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Review
Health Care Sciences & Services
Jason T. Alexander, Erin M. Staab, Wen Wan, Melissa Franco, Alexandra Knitter, M. Reza Skandari, Shari Bolen, Nisa M. Maruthur, Elbert S. Huang, Louis H. Philipson, Aaron N. Winn, Celeste C. Thomas, Meltem Zeytinoglu, Valerie G. Press, Elizabeth L. Tung, Kathryn Gunter, Brittany Bindon, Sanjay Jumani, Neda Laiteerapong
Summary: SGLT2Is show durable reductions in cardiovascular risk factors compared to both placebo and other anti-hyperglycemic medications. Reductions in macrovascular complications and mortality were observed only in comparisons with placebo, with insufficient data for longer-term outcomes in comparisons with other anti-hyperglycemic medications. An increased risk of genital yeast infections was observed for both genders in comparisons with placebo and other anti-hyperglycemic medications.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2022)
Article
Endocrinology & Metabolism
Feifei Zhou, Nannan Du, Lulin Zhou, Chenxi Wang, He Ren, Qiang Sun
Summary: This meta-analysis demonstrates that sotagliflozin has an acceptable safety profile in patients with diabetes, with adverse events including genital mycotic infection, related-to-acidosis events, diarrhea, volume depletion, and severe nocturnal hypoglycemia events. The subgroup analysis of sotagliflozin dosage is of great clinical significance for guiding the use of sotagliflozin in patients with diabetes in the future.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Xindong Liu, Ying Chen, Tao Liu, Ling Cai, Xiaofeng Yang, Chuan Mou
Summary: This study systematically evaluated the effect of SGLT2 inhibitors on adipose tissue in patients with type 2 diabetes. Meta-analysis results showed that the use of these inhibitors significantly reduced visceral adipose tissue, subcutaneous adipose tissue, body weight, and triglycerides in type 2 diabetes patients, which may be attributed to their protective effect on the cardiovascular system.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Rahul Aggarwal, Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Darren K. Mcguire, Silvio E. Inzucchi, Renato D. Lopes, Michael J. Davies, Phillip Banks, Bertram Pitt, Philippe Gabriel Steg
Summary: This study assessed the efficacy of Sotagliflozin on heart failure clinical outcomes in individuals with different baseline glycosylated hemoglobin levels. The results showed that Sotagliflozin reduced heart failure outcomes, regardless of baseline HbA1c.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Review
Endocrinology & Metabolism
Sha Zhang, Zhan Qi, Yidong Wang, Danfei Song, Deqiu Zhu
Summary: SGLT2 inhibitors have positive effects on weight loss and fat reduction in patients with type 2 diabetes, but they may also cause muscle mass loss and increase the risk of sarcopenia.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Pharmacology & Pharmacy
Xingyun Zhu, Chu Lin, Li Li, Suiyuan Hu, Xiaoling Cai, Linong Ji
Summary: SGLT2 inhibitors treatment increases plasma fasting glucagon levels in patients with diabetes, potentially leading to reduced insulin levels and elevated ketone body levels.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Yi-Wen Yu, Xue-Mei Zhao, Yun-Hong Wang, Qiong Zhou, Yan Huang, Mei Zhai, Jian Zhang
Summary: The study found that SGLT2 inhibitors had no significant impact on cardiac structural parameters in type 2 diabetes patients, but improved left ventricular ejection fraction in heart failure patients. It also had a positive effect on cardiac diastolic function, plasma NT-proBNP level, and KCCQ score.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Carolyn S. P. Lam, Chinthanie Ramasundarahettige, Kelley R. H. Branch, Naveed Sattar, Julio Rosenstock, Richard Pratley, Stefano Del Prato, Renato D. Lopes, Elisabeth Niemoeller, Nardev S. Khurmi, Seungjae Baek, Hertzel C. Gerstein
Summary: The analysis of the AMPLITUDE-O trial suggests that the efficacy and safety of Efpeglenatide are not impacted by concurrent use of SGLT2 inhibitors. These data support the combined use of SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.
Review
Pharmacology & Pharmacy
Li Liu, Fang-Hong Shi, Hua Xu, Yue Wu, Zhi-Chun Gu, Hou-Wen Lin
Summary: Ertugliflozin is effective and well tolerated in patients with type 2 diabetes compared to placebo or other hypoglycemic agents, with the exception of an increased risk of genital mycotic infection.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Hidekatsu Fukuta, Hiromi Hagiwara, Takeshi Kamiya
Summary: This meta-analysis aims to evaluate the efficacy and safety of SGLT-2 inhibitors in patients with HFpEF, focusing on outcomes such as HF severity and health-related quality of life.
Review
Cardiac & Cardiovascular Systems
Husam M. Salah, Subhi J. Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L. Mehta, J. Paul Mounsey, Stephen J. Greene, Darren K. McGuire, Renato D. Lopes, Marat Fudim
Summary: This systematic review and meta-analysis examined the efficacy and safety of initiating SGLT2 inhibitors in patients hospitalized with acute heart failure (AHF). The results showed that initiating SGLT2 inhibitors during hospitalization or early post-discharge reduced the risk of rehospitalization for heart failure and improved patient-reported outcomes with no excess risk of adverse effects.
CARDIOVASCULAR DIABETOLOGY
(2022)
Review
Pharmacology & Pharmacy
Shiwen Yang, Ying Liu, Shengzhao Zhang, Fengbo Wu, Dan Liu, Qingfang Wu, Hanrui Zheng, Ping Fan, Na Su
Summary: This study conducted a systematic review and network meta-analysis to evaluate the risk of diabetic ketoacidosis (DKA) in patients with type 2 diabetes mellitus (T2DM) treated with SGLT2 inhibitors. The findings showed that neither SGLT2 inhibitors nor other active antidiabetic drugs were associated with an increased risk of DKA compared to placebo. The use of canagliflozin was found to have a higher DKA risk compared to other SGLT2 inhibitors.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Cheng-Yang Hsieh, Sheng-Feng Sung
Summary: Chronic kidney disease (CKD) is a significant risk factor for stroke and cerebrovascular disease, yet the interaction between the brain and kidneys has received less attention compared to the interaction between the heart and kidneys. This article focuses on the potential of SGLT2 inhibitors, a class of oral anti-diabetic drugs, in preventing strokes and improving the cerebro-renal interaction, regardless of diabetes status. The authors propose the roles of baseline renal functions and dual inhibition of SGLT1/2 in stroke prevention, as well as the additional benefits of reducing atrial fibrillation and hemorrhagic stroke.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)